Company Overview

Omeros Corporation is a U.S.-based biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic, inflammatory, and central nervous system disorders. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with research programs centered on complement-mediated diseases, addiction, and neurodegenerative conditions. Historically, Omeros generated commercial revenue from OMIDRIA, an ophthalmic product used during cataract surgery, although rights to the product were later divested while the company retained certain economic interests tied to royalties and milestones.

The company’s primary value drivers are its proprietary therapeutic pipeline and intellectual property portfolio, particularly programs involving the lectin pathway of the complement system and phosphodiesterase inhibition technologies. Omeros has positioned itself around targeted therapies for rare and difficult-to-treat diseases, emphasizing biologic and small-molecule approaches with potential orphan-drug applications. Founded in 1994 and headquartered in Seattle, Washington, the company evolved from an early-stage platform biotechnology company into a clinically focused biopharmaceutical developer with multiple investigational assets and prior commercial-stage operations.

Business Operations

Omeros conducts its operations primarily through integrated research, clinical development, regulatory, and corporate functions rather than through broad diversified reporting segments. Its business model has historically relied on a combination of licensing arrangements, product royalties, collaboration agreements, and capital market financing to support research and development activities. The company’s therapeutic programs include complement inhibitors targeting mannan-binding lectin-associated serine protease-2 (MASP-2), as well as programs involving phosphodiesterase targets relevant to addiction and neurological disorders.

Operations are concentrated in the United States, though the company has pursued regulatory, licensing, and intellectual property activities internationally. Omeros has entered into partnerships and commercialization arrangements related to OMIDRIA, including transactions involving Rayner Surgical Group and other counterparties associated with ophthalmic commercialization rights. The company maintains control over a portfolio of patents and proprietary technologies tied to complement biology and G protein-coupled receptor-related programs. Public filings also indicate continued investment in clinical-stage assets and regulatory interactions with U.S. and international health authorities.

Strategic Position & Investments

Omeros’ strategic direction has focused on advancing late-stage and clinical-stage therapeutic candidates in rare and specialty disease markets where limited treatment options may support premium pricing and orphan-drug positioning. A major strategic emphasis has been the development of narsoplimab, a MASP-2 inhibitor studied for hematologic and complement-mediated disorders. The company has also invested in broader complement pathway research and central nervous system programs involving phosphodiesterase inhibition and opioid-related indications.

The company has pursued capital allocation toward internal pipeline development rather than broad diversification through large-scale acquisitions. Strategic transactions have included the monetization and transfer of commercial rights associated with OMIDRIA, allowing Omeros to redirect resources toward research programs. Omeros has continued to emphasize biologics, immunology, and precision-targeted therapeutics as core areas of long-term development. Public disclosures and investor materials also highlight ongoing efforts to expand intellectual property protection and pursue regulatory opportunities in rare disease categories.

Geographic Footprint

Omeros is headquartered in Seattle, Washington, and its principal operational activities are centered in the United States. The company’s clinical development, regulatory engagement, and intellectual property activities, however, have extended into multiple international markets through trial sites, patent filings, and commercialization-related agreements. Its products and investigational assets have had relevance to healthcare providers and regulators in North America, Europe, and select additional international markets.

Although Omeros does not maintain the same multinational operating scale as larger pharmaceutical companies, it has established an international presence through licensing arrangements, clinical collaborations, and regulatory submissions. The company’s strategic activities have included engagement with agencies such as the U.S. Food and Drug Administration and European regulatory bodies tied to orphan and specialty therapeutics.

Leadership & Governance

Omeros was founded by Gregory A. Demopulos, who has served as a central figure in the company’s strategic and scientific direction. Leadership has consistently emphasized innovation in immunology, complement biology, and neuroscience-focused therapeutics, with a long-term strategy centered on internally developed platform technologies and targeted clinical development. Corporate governance and operational oversight are conducted through executive leadership and the company’s board of directors, as described in public filings including SEC filings and annual reports.

Key executives have included:

• Gregory A. Demopulos – Chairman, Chief Executive Officer, and President
• Michael A. Jacobsen – Vice President, Chief Accounting Officer, and Treasurer
• Diane L. Blough – Vice President of Regulatory Affairs
• Steven M. Whitcup – Chief Medical Officer

Executive roles and titles may change over time based on corporate filings and governance updates. Public information regarding certain leadership positions may vary across reporting periods.